5/17/2023 7:08:29 AM
Spectrum Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
5/9/2023 7:50:36 AM
Spectrum Pharma Q1 Net Loss From Cont. Opns $5.0 Mln Or $0.02/shr Vs Net Loss $15.4 Mln Or $0.09/shr Prior Year
4/25/2023 6:42:40 AM
Assertio To Buy Spectrum In All-stock And Contingent Value Rights Transaction
3/22/2023 8:11:52 AM
Spectrum Pharmaceuticals Reports Q4 Net Sales Of $10.11 Mln
1/31/2023 7:18:48 AM
Spectrum Pharma Expects Q4 Net Sales To Be About $10 Mln
1/4/2023 7:10:31 AM
Spectrum Pharma Says Francois Lebel EVP And Chief Medical Officer, Will Step Down
12/6/2022 7:05:18 AM
Spectrum's ROLVEDON Injection Added To NCCN Supportive Care Guidelines In Oncology For Hematopoietic Growth Factors
11/25/2022 6:04:58 AM
Spectrum Pharma Gets CRL For NDA For Poziotinib In Patients With HER2 Exon 20 Insertion Mutations In NSCLC
10/21/2022 7:15:45 AM
Spectrum Pharma Announces Commercial Availability Of ROLVEDON Injection
5/11/2022 7:09:00 AM
Spectrum Pharmaceuticals Appoints Nora Brennan As CFO, Effective May 25
4/11/2022 7:03:49 AM
Spectrum Pharma: FDA Accepts BLA Resubmission For Eflapegrastim; Sets PDUFA Goal Date Of Sept. 9
2/11/2022 7:07:11 AM
Spectrum Pharma Announces Acceptance Of New Drug Application Filing For Poziotinib